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Abstract
Introduction: Apolipoprotein M (apoM) is present in 5% of high-density lipoprotein (HDL) particles in plasma. It is
a carrier of sphingosine-1-phosphate (S1P), which is important for vascular barrier protection. The aim was to
determine the plasma concentrations of apoM during sepsis and systemic inflammatory response syndrome (SIRS)
and correlate them to levels of apolipoprotein A-I (apoA1), apolipoprotein B (apoB), HDL-, and low-density
lipoprotein (LDL)-cholesterol.
Methods: Plasma samples from patients with (1), severe sepsis with shock (n = 26); (2), severe sepsis without shock
(n = 44); (3), sepsis (n = 100); (4), infections without SIRS (n = 43); and (5) SIRS without infection (n = 20) were
analyzed. The concentrations of apoM, apoA1, and apoB were measured with enzyme-linked immunosorbent
assays (ELISAs). Total, HDL-, and LDL-cholesterol concentrations were measured with a commercial HDL/LDL
cholesterol test.
Results: ApoM concentrations correlated negatively to acute-phase markers. Thus, apoM behaved as a negative
acute-phase protein. Decreased values were observed in all patient groups (P < 0.0001), with the most drastic
decreases observed in the severely sick patients. ApoM levels correlated strongly to those of apoA1, apoB, HDL,
and LDL cholesterol. The HDL and LDL cholesterol levels were low in all patient groups, as compared with controls
(P < 0.0001), in particular, HDL cholesterol. ApoA1 and apoB concentrations were low only in the more severely
affected patients.
Conclusions: During sepsis and SIRS, the plasma concentrations of apoM decrease dramatically, the degree of
decrease reflecting the severity of the disease. As a carrier for barrier-protective S1P in HDL, the decrease in apoM
could contribute to the increased vascular leakage observed in sepsis and SIRS.
Introduction
Apolipoprotein M (25 kDa) is associated mainly with
HDL and, to a minor extent, with apoB-containing lipo-
proteins [1,2]. It is anchored to the lipoprotein particles
with a retained signal peptide [1,3,4]. Its normal plasma
concentration is approximately 23 mg/L (0.9 μM). In
normal plasma, it has been estimated that around 5% of
HDL particles contain an apoM molecule [5]. The
plasma concentration of apoM correlates with the
plasma levels of total, HDL, and LDL cholesterol [6].
ApoM is a member of the lipocalin protein family, a
group of proteins with a characteristic coffee filter-like
structure and a hydrophobic binding pocket [2,7]. The
elucidation of the three-dimensional structure revealed
that apoM has the ability to bind sphingosine-1-phos-
pate (S1P), an important bioactive lipid mediator known
to be associated with HDL [8-13]. In plasma, approxi-
mately 60% of S1P is bound to HDL, 5% to LDL, and
the rest to albumin. ApoM is the protein in HDL that
binds S1P, and it was recently shown that endothelium-
protective effects of S1P are provided by S1P bound to
the HDL-associated apoM [8].
S1P can activate five different G-protein-coupled
receptors present on many different cells, and it is
involved in regulation of many cellular functions,
including migration, angiogenesis, adhesion,
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inflammation, and rearrangement of the cytoskeleton
[10-13]. The concentration of S1P is higher in blood
and lymph as compared with interstitial fluid (for exam-
ple, in the lymphoid organs), and the S1P gradient is
important for the trafficking of immune cells (for exam-
ple, the egress of lymphocytes from the thymus and
other lymphoid organs). S1P is also important for the
cell-to-cell contacts of endothelium that regulate the
basal barrier function and inflammation-induced vascu-
lar leak. In this context, it is noteworthy that the expres-
sion of apoM in both liver and kidney decreases during
inflammation, which results in decreased plasma levels
of apoM [14].
The acute-phase response (APR) can be triggered by
infections or other causes of inflammation, such as tis-
sue trauma, ischemic necrosis, and malignancies [15].
The APR is characterized by increased concentrations of
certain plasma proteins (for example, serum amyloid A
(SAA), C-reactive protein (CRP), a1-antitrypsin, and
fibrinogen), whereas others decrease, such as albumin
and transferrin. These changes are caused by the influ-
ence of inflammatory cytokines on transcription factors
that control the rate of synthesis of the different pro-
teins. The lipid and lipoprotein profiles are dramatically
changed during the APR [16-19]. The plasma concentra-
tions of total cholesterol, HDL, and LDL cholesterol
decrease, whereas triglyceride and very low-density lipo-
protein (VLDL) levels increase. The plasma levels of
apoA1 decrease during APR, and the protein composi-
tion of acute-phase HDL changes drastically, SAA
becoming the dominating protein. HDL is part of the
innate immune defense, being able to bind and neutra-
lize lipopolysaccharide (LPS), an activity shared with the
other lipoproteins. The LPS-binding activity of the lipo-
proteins increases during the acute-phase reaction
because of the increased levels of LPS-binding protein
(LBP) [20,21]. SAA-containing HDL has a higher elimi-
nation rate than normal HDL, which adds to the effi-
ciency of LPS elimination from circulation. Other
important changes in HDL that affect the function of
HDL include decreased levels of lecithin cholesterol acyl
transferase (LCAT), cholesterol ester transfer protein
(CETP), and the antioxidant enzyme paraoxonase 1
(PON-1), whereas LBP and the activities of phospholipid
transfer protein (PLTP) and platelet-activating factor
acetylhydrolase (PAF-AH) increase. As a result of these
changes, the reverse cholesterol transport capacity of
HDL decreases, and HDL loses its antioxidant and anti-
inflammatory properties [16-19,22].
Sepsis, which causes a severe form of APR and sys-
temic inflammatory response syndrome (SIRS), is a lead-
ing cause of mortality in noncoronary intensive care
units [23-26]. The yearly incidence is approximately
three cases per 1,000 individuals, and the mortality is
high. The severe forms of sepsis, which cause septic
shock, result in severely decreased plasma levels of HDL
cholesterol, apoA-1, apoC1, and CETP, and these factors
have been suggested to be independent predictors of
survival [27-32].
ApoM is a negative acute-phase protein that decreases
during infection and inflammation [14]. In a pilot study
including six patients with sepsis, the plasma concentra-
tion of apoM, estimated by semiquantitative Western
blotting, was found to be decreased to around 60%, as
compared with the apoM levels after recovery [14]. This
observation called for a larger study of apoM in sepsis
and SIRS. The aim of this study was to investigate the
apoM concentration in plasma in a large cohort of
patients with sepsis and SIRS. We report that the apoM
plasma levels were drastically decreased in all patients,
and a strong relation was seen between the decrease of
apoM and the severity of the disease.
Materials and methods
Study population
The study cohort that included 232 patients was pre-
viously described in detail [33]. In brief, the patients
were recruited in a prospective study at the Clinic for
Infectious Diseases, University Hospital, Lund, Sweden.
The criteria for inclusion were fever (≥ 38°C) and a sus-
pected infection, and only patients older than 18 years
were included. Citrated plasma was collected within 12
hours after admission to the hospital. Healthy controls
from the local blood bank (n = 97) served as controls.
Patients and controls were not fasting at the time of
blood collection.
The patients were judged by the SIRS criteria (that is,
body temperature ≥ 38°C, white blood cell count (WBC)
> 12 × 109/L or < 4 × 109/L, pulse rate > 90/minute,
and respiratory rate > 20/minute [34], by significant
hypotension, with a systolic blood pressure of < 90 mm
Hg or a decrease of > 40 mm Hg from baseline, and by
the presence or absence of organ failure, as well as the
final diagnosis. Based on the criteria, the patients were
divided into the following groups: (1), severe sepsis with
shock (n = 26); (2), severe sepsis without shock (n =
44); (3), sepsis (n = 100); (4), infections without SIRS (n
= 43); and (5) SIRS without infection (n = 20) [33].
Severe sepsis was defined as an infectious disease and
at least two SIRS criteria, and the presence or develop-
ment of hypotension and/or organ failure within 24
hours of the collection of the blood samples [33]. Septic
shock was severe sepsis with hypotension that required
vasopressor support or a persistent hypotension for
more than 1 hour despite adequate fluid resuscitation.
Sepsis was defined as an infectious disease, at least two
SIRS criteria, but no presence or development of organ
failure. Infection was defined as an infectious disease
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without SIRS. SIRS without infections had at least two
SIRS criteria and one of the following diseases: systemic
vasculitis, cardiac failure, gastrointestinal bleeding, pul-
monary embolism, corticosteroid deficiency due to
hypopituitarism, dehydration, or urine retention [33].
The ethics committee of Lund University approved
the project protocol (number 790/2005), and informed
consent was obtained from all patients or their close
relatives.
Analysis of apoA1, apoB, and apoM
The ApoM ELISA was described previously [6]. In brief,
96-well Costar plates (Corning, Inc., Lowell, MA, USA)
were coated with a catching monoclonal apoM antibody
(mAb 58) before blocking with a quenching solution.
The samples were diluted in detergent-containing buffer
and incubated overnight. The bound apoM was detected
by using a biotinylated secondary apoM antibody (mAb
42) in combination with streptavidin-avidin-horseradish
peroxidase and 1,2-phenylenediamine dihydrochloride
(Dako, Glostrup, Denmark). The 490-nm absorbance
was measured and compared with a plasma standard
curve having known amounts of apoM.
ApoA1 and apoB also were measured with ELISA
assays, which were similar in design to the apoM ELISA.
For apoA1, a polyclonal antibody against apoA1 (Q0496;
Dako) was used as catcher, whereas an apoA1 monoclo-
nal antibody (mAb25) made in the laboratory was used
as the detecting antibody. For apoB, a polyclonal anti-
body directed against apoB (Q0497; Dako) was used as a
catcher, and an apoB monoclonal antibody (ACC-
250319; Nordic Biosite, Täby, Sweden) was used as a
detecting antibody.
Analysis of HDL, LDL, and total cholesterol
Plasma concentrations of HDL cholesterol, LDL cho-
lesterol, and total cholesterol were measured with the
combined HDL/LDL cholesterol kit (EHDL-100;
Bioassay Systems, Hayward, CA, USA). The kit is
based on a polyethylene glycol (PEG) precipitation in
which HDL and LDL/VLDL are separated, and the
cholesterol concentrations then were determined by
using cholesterol esterase/cholesterol dehydrogenase
reagent.
Statistical analysis
Nonparametric tests were used throughout the study.
The Mann-Whitney U test was used for evaluating the
difference between different groups, and the Spearman
rank correlation coefficient, for evaluating correlations.
For all tests, P < 0.05 was considered significant. Graph-
pad Prism 4.0 (Graphpad Software, La Jolla, CA, USA)
was used for statistics.
Results
Patients
The study included 232 patients with fever and sus-
pected infection, of whom 26 were found to have severe
sepsis with shock; 44 had severe sepsis without shock;
99 had sepsis; 43 had infections without SIRS; and 20
had SIRS without infections. Patient demographic details
and diagnoses were presented elsewhere [33]. Urinary
tract infections and pneumonia were common, in parti-
cular in the sepsis groups, whereas upper respiratory
infections dominated in patients without SIRS. The
patients with noninfectious SIRS had various diseases
(for example, vasculitis, cardiac failure, gastrointestinal
bleeding, pulmonary embolism, or pancreatitis). In the
whole patient population, the mortality was 3.4%; in the
severe-sepsis groups, it was 10%, and in the severe-sep-
sis group with shock, it was 19%.
HDL, LDL, and total cholesterol plasma concentrations
The plasma concentrations of total cholesterol and HDL
and LDL cholesterol demonstrated similar patterns of
variation between the five patient groups, with the
most-pronounced decreases seen in patients with severe
sepsis with shock, followed by the severe sepsis group
without shock, and the patients with SIRS without infec-
tions (Figure 1). In all patient groups, the levels of total,
LDL, and HDL cholesterol were highly significantly
lower (P < 0.001) than in controls. In the most severely
affected groups, the median cholesterol levels were >
50% of the corresponding levels of the controls (Table
1). It was noteworthy that in the group with severely
sick patients with SIRS but without infections, the cho-
lesterol levels were equally low or lower than the choles-
terol levels of the most severely affected sepsis group.
ApoA1, ApoB, and apoM plasma concentrations
The plasma concentrations of apoA1, apoB, and apoM
demonstrated a similar pattern of variation between the
five patient groups (Figure 2). The most pronounced
decreases were observed in patients with severe sepsis
with shock, followed by the severe sepsis group without
shock and the patients with SIRS without infections.
ApoA1 levels were lowest in patients with severe sepsis
with shock and also in the SIRS group without infec-
tions, and both groups were highly significantly different
from the control group (P < 0.001) (Table 1). The
apoA1 in the group having severe sepsis minus shock
differed less from the apoA1 in controls, but the differ-
ence was still significant (P = 0.0127). ApoB levels were
less affected and was significantly lower than controls
only in patients with severe sepsis and shock (P <
0.001). The plasma levels of apoM in the five patient
groups were all highly significantly lower than the apoM
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in controls (P < 0.001 for all groups). In the three sepsis
groups, the lowest apoM levels were found in the group
with severe sepsis and shock, followed by the severe sep-
sis group without shock and the sepsis group. The
group with SIRS without infection also demonstrated
very low apoM levels. ApoM levels in the patient group
with infections without SIRS were also significantly
lower than apoM levels in controls. Thus, among the
apolipoproteins tested, apoM demonstrated the largest
differences compared with the controls.
Correlations between apoM and other plasma analytes
Several other analytes were previously tested in this
cohort of patients [33], and the correlation between the
concentrations of apoM and these analytes were tested
(Table 2). The strongest positive correlation was to
apoA1 (r = 0.52; P < 0.001), to total cholesterol (r =
0.48; P < 0.0001), and to LDL cholesterol (r = 0.46; P <
0.0001). Lower, but significant correlations to apoB (r =
0.28; P < 0.0001) and HDL cholesterol (r = 0.24; P =
0.0014) were observed. Strong negative correlations to
the acute-phase markers HBP (heparin-binding protein),
procalcitonin, CRP, and IL-6 were observed.
Discussion
Sepsis is associated with a strong acute-phase response
resulting in pronounced changes in the concentrations
of many plasma proteins [17,18,23,26]. This also is true
for the lipoproteins, which change in both lipid and pro-
tein content [16-19]. HDL is more affected by the acute-
phase response than is LDL, with a drastic decrease in
the content of cholesterol-esters and changes in protein
composition. The concentrations of apoAI and apoAII
decrease, and the acute-phase protein SAA increases to
the extent that it can become the dominating protein in
acute-phase HDL. HDL-associated enzymes PON-1,
LCAT, and CETP decrease, and the changes in lipid and
plasma composition affect the function of HDL, acute-
phase HDL being less efficient in reverse cholesterol
transport, in antioxidant, and in antiinflammatory activ-
ities. We now add to the list of major protein changes
in HDL during the acute phase by describing the drastic
decrease in apoM concentrations during the acute-phase
response and SIRS, regardless of the causative factor.
Under normal conditions, the major part of apoM is
associated with HDL [2,5]. Recently, it was revealed that
apoM is the carrier of S1P in HDL [8,9]. S1P bound to
apoM provides HDL with a number of vasculoprotective
effects, which are mediated by S1P interacting with the
S1P1 receptor on endothelium [35]. This provides a
tonic stimulus to the S1P1 receptor, which is important
for the formation of endothelial adherens junctions that
are crucial for the vascular barrier function [10]. The
drastic decrease in apoM plasma concentrations caused
by the severe acute-phase response of sepsis presumably
results in decreased S1P concentrations and, as a conse-
quence, decreased barrier function. Increased vascular
leakage is a hallmark of sepsis, and it is likely that the
decrease in S1P-associated apoM would contribute to
this. ApoM has also been shown to have antioxidant
properties, protecting LDL against oxidative injury
[5,36]. This function of apoM is likely impaired during
the sepsis, which would add to the decreased antioxida-
tive capacity of HDL that is additionally caused by the


























































   
   
































   
   





   
Figure 1 Plasma concentrations of total, low-density-
lipoprotein (LDL), and high-density-lipoprotein (HDL)
cholesterol in the patients. The bars represent the median values
(detailed in Table 1).
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The low plasma concentrations of apoM during sepsis
are either the result of decreased transcription of the
apoM gene or of the shortened half-life of apoM-con-
taining lipoproteins. ApoM is expressed in the liver and
kidney. Systemic inflammation induced by injection of
LPS, zymosan, or turpentine into mice results in
decreased apoM mRNA levels in both liver and kidney
[14]. Moreover, addition of TNF or IL-1 to Hep3B hepa-
toma cell cultures decreases apoM mRNA levels. These
results are consistent with the conclusion that apoM is
a negative acute-phase protein, the expression of which
decreases during inflammatory conditions. The apoM
gene transcription is under the control of multiple tran-
scription factors. Hepatocyte nuclear factor 1a (HNF-
1a), liver receptor homolog 1 (LRH-1), and Forkhead
box A2 increase the expression of the apoM gene
[37-39]. In this context, it is interesting to note that
HNF-1a is downregulated by LPS during the acute-
phase response [40]. Moreover, it was recently demon-
strated that members of the AP-1 family of proinflam-
matory transcription factors (c-Jun and JunB) compete



































































































The medians and ranges are given. The CRP levels for controls were not analyzed (NA); the local normal range for CRP was < 3 mg/L. The asterisks indicate the
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Figure 2 Plasma concentrations of apolipoprotein (apo)AI,
apoB, and apoM in the patients. The bars represent the median
values (detailed in Table 1).
Table 2 Correlations between the plasma concentrations
of apoM and those of several different analytes tested
Analytes r value P value
Total cholesterol 0.48 < 0.0001
HDL cholesterol 0.24 0.0014
LDL cholesterol 0.46 < 0.0001
ApoA1 0.52 < 0.0001
ApoB 0.28 < 0.0001
Interleukin 6 -0.29 < 0.0001
Procalcitonin -0.41 < 0.0001
Lactate -0.35 < 0.0001
C-reactive protein -0.34 < 0.0001
Heparin-binding protein (HBP) -0.35 < 0.0001
Spearman rank-correlation test was used.
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with HNF-1a for binding to the same regulatory region
in the apoM promotor [37]. Increased c-Jun and JunB
levels during the acute-phase response thus mediate
decreased apoM gene transcription and synthesis of
apoM. Similar mechanisms account for the decrease in
apoA-II and possibly other apolipoproteins during the
acute-phase response. Taken together, this suggests that
the decrease in apoM levels during acute-phase reac-
tions is mostly explained by decreased transcription of
the apoM gene, in analogy to the actions of the other
negative acute-phase apolipoproteins.
Acute-phase proteins are used clinically as markers of
disease severity and as prognostic factors [23,26]. Nega-
tive acute-phase proteins can be used in a similar man-
ner, even though this is less commonly the case. Several
studies have demonstrated that the magnitude of
decrease of lipid and apolipoprotein levels has a predic-
tive prognostic value in sepsis. Thus, very low levels of
cholesterol fractions (HDL, LDL, and total), apoAI,
apoC1, and CETP have been associated with poor survi-
val [27-32]. The pronounced decrease in apoM levels in
patients with severe sepsis, and also in those with SIRS
without infection, suggests that apoM may be a useful
marker for severity of disease and prognosis. In the pre-
sent study, the mortality rate was low, and the power of
the study was not sufficient to elucidate the predictive
power of apoM plasma concentrations.
Conclusions
We find that, in response to severe sepsis and SIRS of
other causes, the plasma levels of apoM demonstrate a
decrease, which is more pronounced than those of
apoAI and apoB. This suggests that the vasculoprotec-
tive effects of apoM and its ligand S1P decrease during
the acute-phase response. It remains to be elucidated
whether apoM and S1P levels have prognostic value and
whether changes in apoM levels contribute to the
pathogenesis of SIRS and septic shock.
Key messages
• apoM plasma concentrations are decreased in
patients with sepsis, SIRS, and infections compared
with controls
• apoM behaves as a negative acute-phase protein
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